How to buy Aziyo Biologics (AZYO) stock

Aziyo Biologics, Inc is a medical devices business based in the US. Aziyo Biologics shares (AZYO) are listed on the NASDAQ and all prices are listed in US Dollars. Aziyo Biologics employs 171 staff and has a trailing 12-month revenue of around 0.00.

Aziyo Biologics stock price (NASDAQ: AZYO)

Use our graph to track the performance of AZYO stocks over time.

Aziyo Biologics shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$12.55
52-week range	$7.30 - $18.00
50-day moving average	$9.49
200-day moving average	$12.66
Wall St. target price	$17.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Aziyo Biologics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Aziyo Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aziyo Biologics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aziyo Biologics price performance over time

Historical closes compared with the close of $12.55 from 2021-05-28

1 week (2021-07-16)	N/A
1 month (2021-06-25)	16.53%
3 months (2021-04-27)	4.15%
6 months (2021-01-23)	N/A

1 year (2020-07-23)	N/A
2 years (2019-07-23)	N/A
3 years (2018-07-23)	N/A
5 years (2016-07-23)	N/A

Aziyo Biologics financials

Revenue TTM	$45.7 million
Gross profit TTM	$20.6 million
Return on assets TTM	-12.54%
Return on equity TTM	-740.82%
Profit margin	-48.86%
Book value	$1.61
Market capitalisation	$88.4 million

TTM: trailing 12 months

Shorting Aziyo Biologics shares

There are currently 135,705 Aziyo Biologics shares held short by investors – that's known as Aziyo Biologics's "short interest". This figure is 23.6% down from 177,641 last month.

There are a few different ways that this level of interest in shorting Aziyo Biologics shares can be evaluated.

Aziyo Biologics's "short interest ratio" (SIR)

Aziyo Biologics's "short interest ratio" (SIR) is the quantity of Aziyo Biologics shares currently shorted divided by the average quantity of Aziyo Biologics shares traded daily (recently around 29437.093275488). Aziyo Biologics's SIR currently stands at 4.61. In other words for every 100,000 Aziyo Biologics shares traded daily on the market, roughly 4610 shares are currently held short.

To gain some more context, you can compare Aziyo Biologics's short interest ratio against those of similar companies.

• Vertex Pharmaceuticals Incorporated (VRTX.US): 1.3
• Biogen (BIIB.US): 0.53
• Moderna (MRNA.US): 1.3

However Aziyo Biologics's short interest can also be evaluated against the total number of Aziyo Biologics shares, or, against the total number of tradable Aziyo Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aziyo Biologics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Aziyo Biologics shares in existence, roughly 10 shares are currently held short) or 0.0875% of the tradable shares (for every 100,000 tradable Aziyo Biologics shares, roughly 88 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aziyo Biologics.

Find out more about how you can short Aziyo Biologics stock.

Aziyo Biologics share dividends

We're not expecting Aziyo Biologics to pay a dividend over the next 12 months.

Aziyo Biologics overview

Aziyo Biologics, Inc. , a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc.

Frequently asked questions

What percentage of Aziyo Biologics is owned by insiders or institutions?
Currently 8.756% of Aziyo Biologics shares are held by insiders and 92.438% by institutions. How many people work for Aziyo Biologics?
Latest data suggests 171 work at Aziyo Biologics. When does the fiscal year end for Aziyo Biologics?
Aziyo Biologics's fiscal year ends in December. Where is Aziyo Biologics based?
Aziyo Biologics's address is: 12510 Prosperity Drive, Silver Spring, MD, United States, 20904 What is Aziyo Biologics's ISIN number?
Aziyo Biologics's international securities identification number is: US05479K1060